Nihon Kohden Corporation Stock

Equities

6849

JP3706800004

Advanced Medical Equipment & Technology

Delayed Japan Exchange 02:00:00 2024-04-25 am EDT 5-day change 1st Jan Change
4,238 JPY -0.75% Intraday chart for Nihon Kohden Corporation +3.06% -5.04%
Sales 2024 * 222B 1.43B Sales 2025 * 230B 1.48B Capitalization 358B 2.3B
Net income 2024 * 15.82B 102M Net income 2025 * 16.02B 103M EV / Sales 2024 * 1.36 x
Net cash position 2024 * 56.11B 361M Net cash position 2025 * 64.25B 413M EV / Sales 2025 * 1.28 x
P/E ratio 2024 *
22.9 x
P/E ratio 2025 *
22.7 x
Employees 5,751
Yield 2024 *
1.43%
Yield 2025 *
1.44%
Free-Float 94.59%
More Fundamentals * Assessed data
Dynamic Chart
Japanese Shares End in Green as Yen Weakens MT
Nihon Kohden to Book Extraordinary Gains of 4 Billion Yen in Fiscal Q4 Following Adjustment in Retirement Plan MT
Nihon Kohden Repurchases 1.1 Billion Yen Worth of Shares MT
Tranche Update on Nihon Kohden Corporation's Equity Buyback Plan announced on February 2, 2024. CI
Nihon Kohden Corporation's Equity Buyback announced on February 2, 2024, has closed with 250,000 shares, representing 0.3% for ¥1,123.75 million. CI
Nihon Kohden Corporation announces an Equity Buyback for 250,000 shares, representing 0.3% for ¥1,123.75 million. CI
Nihon Kohden Corporation authorizes a Buyback Plan. CI
Nihon Kohden Corporation Sets New Standard for Central Nursing with the Launch of CNS-2101 CI
Nihon Kohden Corporation Provides Final Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Nihon Kohden Corporation Announces Interim Second Quarter Dividend for the Fiscal Year Ending March 31, 2024 CI
Nihon Kohden Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Nihon Kohden Corp Revises Forecast for Fiscal H1 Upwards to Reflect Stronger Sales, Weaker-than-Expected Yen MT
Nihon Kohden Corporation Revises Consolidated Earnings Guidance for the First Half Ended September 30, 2023 CI
Nihon Kohden Corporation Unveils Groundbreaking One View Solution Powered by the Neuromaster G1 for Vital Signs Integration in Intraoperative Neuromonitoring CI
Nihon Kohden Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending March 31, 2024 CI
More news
1 day-0.75%
1 week+3.06%
Current month+5.84%
1 month+7.56%
3 months-6.53%
6 months+20.84%
Current year-5.04%
More quotes
1 week
4 088.00
Extreme 4088
4 311.00
1 month
3 810.00
Extreme 3810
4 311.00
Current year
3 810.00
Extreme 3810
4 783.00
1 year
3 372.00
Extreme 3372
4 783.00
3 years
2 762.00
Extreme 2762
4 783.00
5 years
2 556.00
Extreme 2556
4 783.00
10 years
1 914.00
Extreme 1914
4 783.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 95-03-31
Chief Tech/Sci/R&D Officer - 84-03-31
Chief Administrative Officer 64 14-03-31
Members of the board TitleAgeSince
Director/Board Member 72 16-05-31
Director/Board Member 70 22-05-31
Director/Board Member 61 85-03-31
More insiders
Date Price Change Volume
24-04-25 4,238 -0.75% 203 100
24-04-24 4,270 +1.45% 201,900
24-04-23 4,209 +0.57% 301,000
24-04-22 4,185 +2.17% 244,000
24-04-19 4,096 -0.39% 425,500

Delayed Quote Japan Exchange, April 25, 2024 at 02:00 am EDT

More quotes
NIHON KOHDEN CORPORATION is a Japan-based company engaged in the research, development, manufacture and sale of medical electronic equipment, as well as the provision of maintenance and repair services. The Company mainly operates medical electronics related business. The Company offers electroencephalograph, electromyographic, evoked potential testing equipment, electrocardiographs, cardiac catheterization equipment, diagnostic information systems and related consumables (paper, electrodes, catheters and others), biological information monitors, clinical information systems, artificial respiration, artificial ear, hemocytometer, ultrasonic diagnostic equipment, research equipment and transformers, among others. The Company is also engaged in the sales promotion for its products, as well as the general affair-related and manpower dispatching businesses.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4,270 JPY
Average target price
4,465 JPY
Spread / Average Target
+4.57%
Consensus